NRIX — Nurix Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1549595 ·
Last close
$14.24
Market Cap
$1.56B
52W High
$28.23
52W Low
$12.43
ADV30
3,578,968
Next earnings
2027-01-28

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Aug 2026 673,064,000 — 559,451,000 549,807,000 1,195,298,000 720,242,000 226,987,000
May 2026 9,043,000 — -94,204,000 -89,535,000 535,540,000 67,685,000 132,913,000
Feb 2026 6,252,000 — -92,495,000 -87,174,000 636,130,000 71,195,000 155,237,000
Nov 2025 13,577,000 — -83,095,000 -78,221,000 688,135,000 246,960,000 149,388,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-293,704,000
Investing CF
$19,992,000
Financing CF
$257,204,000
CapEx
$-10,823,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.45
As of
2026-10-17

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,179,935,000
Inventory
—
Receivables
$19,000,000
ST Investments
$375,844,000
EBIT TTM
$-361,179,000
Pretax Income TTM
$-341,622,000
Interest Exp TTM
—
Analysts
14

Yahoo Snapshot (yfinance, live)

Total Revenue
$701,936,000
EBITDA
$297,767,008
Free Cash Flow
$233,337,632
Enterprise Value
$1,684,957,440
Total Cash
$1,048,254,976
Total Debt
$65,332,000
Shares Out
109,249,814
Trailing EPS
$2.38
Book Value
$8.87
ROE
44.0%
ROA
21.1%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Nov 2025 83,980,000 -285,666,000 -264,457,000 688,135,000 149,388,000 538,747,000 -249,465,000
Nov 2024 54,549,000 -213,027,000 -193,569,000 669,343,000 142,350,000 526,993,000 -172,584,000
Nov 2023 76,987,000 -155,063,000 -143,948,000 355,598,000 155,105,000 200,493,000 -81,365,000
Nov 2022 38,627,000 -183,867,000 -180,360,000 416,759,000 113,063,000 303,696,000 -159,807,000

TTM Snapshot

Revenues TTM
$36,766,000
NetIncome TTM
$-341,351,000
OpCashFlow TTM
—
Assets (Latest)
$535,540,000
Forward EPS
$-1.28

Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)

max pain strike: $26.00 · spot: $14.10 · call volume: 437 · put volume: 895

Peers — same industry

TickerNameMarket CapLastDaily %
PGEN PRECIGEN, INC. $1.54B $4.29 —
ADRX ADARx Pharmaceuticals, Inc. $1.53B $13.82 —
SRPT Sarepta Therapeutics, Inc. $1.58B $14.77 —
KLRA Kailera Therapeutics, Inc. $1.58B $12.20 —
ANIP ANI PHARMACEUTICALS INC $1.59B $69.99 —

News headlines (Yahoo Finance, 1h cache)

Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical Officer
2026-11-11 12:00 · Yahoo
Nurix Therapeutics to Participate in Upcoming Investor Conferences
2026-11-10 12:00 · Yahoo
Is Early B Cell Cancer Data Altering The Investment Case For Nurix Therapeutics (NRIX)?
2026-11-07 06:12 · Yahoo
Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition
2026-11-05 12:00 · Yahoo
Nurix, Sanofi Diverge — And One Breaks Out — On A Shocking Eczema Development
2026-11-04 21:19 · Yahoo
NRIX Stock Clocks Worst Day Ever After Sanofi Discontinues Trial Of Licensed Drug: Wells Fargo Slashes Price Target
2026-11-04 21:14 · Yahoo
Sanofi (ENXTPA:SAN) Drops SAR448272 And Backs New Immunology Candidate
2026-11-04 19:14 · Yahoo
Nurix Therapeutics Shares Plunge 28.4% as Sanofi Terminates STAT6 Drug Development Programme
2026-11-04 13:47 · Yahoo
NRIX Slumps 35% After-Hours — What’s Driving The Selloff?
2026-11-03 22:58 · Yahoo
Nurix Therapeutics stock tumbles on Sanofi program termination
2026-11-03 21:54 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.